Author:
Alawak Mohamad,Dayyih Alice Abu,Awak Ibrahim,Gutberlet Bernd,Engelhardt Konrad,Bakowsky Udo
Reference32 articles.
1. Harris L, Batist G, Belt R et al (2002) Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 94:25–36. https://doi.org/10.1002/cncr.10201
2. Thorn CF, Oshiro C, Marsh S et al (2011) Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics 21:440–446. https://doi.org/10.1097/FPC.0b013e32833ffb56
3. Tsang W, Chau SP, Kong S et al (2003) Reactive oxygen species mediate doxorubicin induced p53-independent apoptosis. Life Sci 73:2047–2058. https://doi.org/10.1016/S0024-3205(03)00566-6
4. Perez AT, Domenech GH, Frankel C et al (2002) Pegylated liposomal doxorubicin (Doxil) for metastatic breast cancer: the Cancer Research Network, Inc., experience. Cancer Investig 20(Suppl 2):22–29. https://doi.org/10.1081/cnv-120014883
5. Gabizon A, Catane R, Uziely B et al (1994) Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 54:987–992